Latest news with #Revi
Business Mayor
21-05-2025
- Business
- Business Mayor
OpenAI updates its new Responses API rapidly with MCP support, GPT-4o native image gen, and more enterprise features
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More OpenAI is rolling out a set of significant updates to its newish Responses API, aiming to make it easier for developers and enterprises to build intelligent, action-oriented agentic applications. These enhancements include support for remote Model Context Protocol (MCP) servers, integration of image generation and Code Interpreter tools, and upgrades to file search capabilities—all available as of today, May 21. First launched in March 2025, the Responses API serves as OpenAI's toolbox for third-party developers to build agentic applications atop some of the core functionalities of its hit services ChatGPT and its first-party AI agents Deep Research and Operator. In the months since its debut, it has processed trillions of tokens and supported a broad range of use cases, from market research and education to software development and financial analysis. Popular applications built with the API include Zencoder's coding agent, Revi's market intelligence assistant, and MagicSchool's educational platform. The Responses API debuted alongside OpenAI's open-source Agents SDK in March 2025, as part of an initiative to provide third-party developer access to the same technologies powering OpenAI's own AI agents like Deep Research and Operator. This way, startups and companies outside of OpenAI could integrate the same tech as it offers through ChatGPT into their own products and services, be they internal for employee usage or external for customers and partners. Initially, the API combined elements from Chat Completions and the Assistants API—delivering built-in tools for web and file search, as well as computer use—enabling developers to build autonomous workflows without complex orchestration logic. OpenAI said at that time that the Chat Completions API would be deprecated by mid 2026. The Responses API provides visibility into model decisions, access to real-time data, and integration capabilities that allowed agents to retrieve, reason over, and act on information. This launch marked a shift toward giving developers a unified toolkit for creating production-ready, domain-specific AI agents with minimal friction. A key addition in this update is support for remote MCP servers. Developers can now connect OpenAI's models to external tools and services such as Stripe, Shopify, and Twilio using only a few lines of code. This capability enables the creation of agents that can take actions and interact with systems users already depend on. To support this evolving ecosystem, OpenAI has joined the MCP steering committee. The update brings new built-in tools to the Responses API that enhance what agents can do within a single API call. A variant of OpenAI's hit GPT-4o native image generation model — which inspired a wave of 'Studio Ghibli' style anime memes around the web and buckled OpenAI's servers with its popularity, but can obviously create many other image styles — is now available through the API under the model name 'gpt-image-1.' It includes potentially helpful and fairly impressive new features like real-time streaming previews and multi-turn refinement. This enables developers to build applications that can produce and edit images dynamically in response to user input. Additionally, the Code Interpreter tool is now integrated into the Responses API, allowing models to handle data analysis, complex math, and logic-based tasks within their reasoning processes. The tool helps improve model performance across various technical benchmarks and allows for more sophisticated agent behavior. Improved file search and context handling The file search functionality has also been upgraded. Developers can now perform searches across multiple vector stores and apply attribute-based filtering to retrieve only the most relevant content. This improves the precision of information agents use, enhancing their ability to answer complex questions and operate within large knowledge domains. Several features are designed specifically to meet enterprise needs. Background mode allows for long-running asynchronous tasks, addressing issues of timeouts or network interruptions during intensive reasoning. Reasoning summaries, a new addition, offer natural-language explanations of the model's internal thought process, helping with debugging and transparency. Encrypted reasoning items provide an additional privacy layer for Zero Data Retention customers. These allow models to reuse previous reasoning steps without storing any data on OpenAI servers, improving both security and efficiency. The latest capabilities are supported across OpenAI's GPT-4o series, GPT-4.1 series, and the o-series models, including o3 and o4-mini. These models now maintain reasoning state across multiple tool calls and requests, which leads to more accurate responses at lower cost and latency. Despite the expanded feature set, OpenAI has confirmed that pricing for the new tools and capabilities within the Responses API will remain consistent with existing rates. For example, the Code Interpreter tool is priced at $0.03 per session, and file search usage is billed at $2.50 per 1,000 calls, with storage costs of $0.10 per GB per day after the first free gigabyte. Web search pricing varies based on the model and search context size, ranging from $25 to $50 per 1,000 calls. Image generation through the gpt-image-1 tool is also charged according to resolution and quality tier, starting at $0.011 per image. All tool usage is billed at the chosen model's per-token rates, with no additional markup for the newly added capabilities. With these updates, OpenAI continues to expand what is possible with the Responses API. Developers gain access to a richer set of tools and enterprise-ready features, while enterprises can now build more integrated, capable, and secure AI-driven applications. All features are live as of May 21, with pricing and implementation details available through OpenAI's documentation.
Business Wire
29-04-2025
- Health
- Business Wire
Revi ® System Demonstrates Significant and Sustained Quality of Life Benefits Across All Domains for the Majority of Patients with Urgency Urinary Incontinence at 24 Months
PARK CITY, Utah--(BUSINESS WIRE)-- BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and developer of the Revi ® System, a patient-centric tibial neuromodulation solution for urgency urinary incontinence (UUI), announced today 24-month Quality of Life (QoL) results from the OASIS pivotal study showing sustained and clinically meaningful improvements. The research was presented at the annual meeting of the American Urological Association (AUA) in Las Vegas. UUI is commonly associated with decreased quality of life, an important metric that supports comprehensive quality of clinical care for patients. 1 The OASIS trial showed that Revi demonstrated consistent QoL benefits throughout 24 months, with clinically significant (≥10-point change) and sustainable improvements in symptom severity in all domains of the Overactive Bladder Questionnaire (OAB-q), including coping, concern, sleep and social, and a total transformed Health-Related QoL (HRQL) score of (87.2%). Symptom severity (transformed score), saw highly impactful improvement with a nearly 40-point reduction, from 70.3 to 32.4, 30.6, and 31.5 at six months, 12 months, and 24 months, respectively, Additional study highlights: As previously reported, primary efficacy and safety endpoints were met with a UUI response rate of 79.4% (≥50% decrease in UUI) and no device- or procedure-related serious adverse events. At 24 months, 96.8% reported treatment benefit, 96.7% reported satisfaction, and 100% reported a willingness to continue therapy. Importantly, even in participants who did not meet the efficacy endpoint at 24 months (21%), appreciable therapeutic benefit was still noted; in patients with large leaks within this subgroup, 58.8% reported no large leaks in their 24-month voiding diaries. Additionally, 83.3% reported treatment benefit, 66.7% reported satisfaction, and 100.0% reported a willingness to continue Revi therapy. The OASIS study demonstrates that iTNM with Revi represents a highly effective treatment modality for UUI that results in clinically meaningful and sustainable improvements in both bladder-related and overall health-related QoL. These important QoL improvements were seen within six months of implant activation and were sustained through 24 months. 'OASIS findings presented today continue to underscore the strength of Revi's efficacy alongside improvements in quality of life for people living with disruptive UUI,' said Roger Dmochowski, M.D., Chief Medical Advisor, BlueWind Medical, who presented the research findings. 'UUI can derail active and full lives and is often associated with significant distress. The data presented today builds on an extensive body of evidence supporting Revi as an intervention that restores quality of life for many patients.' About Urge Urinary Incontinence (UUI) and Quality of Life UUI, also known as Urgency Urinary Incontinence, is a chronic condition, which means it won't go away by itself. It can be a disabling condition with physical, psychological, and social consequences that may significantly impact quality of life. 1 UUI is associated with a high negative impact on patient's quality of life, including causing people with symptoms to stay at home, decreasing physical activities and attributing weight gain to an inability to exercise. Women are significantly more likely to report disturbed sleep, decreased self-esteem, decreased sexuality, and feelings of overall declining health related to UUI. 2 About the OASIS Study The OASIS (Overactive Bladder Stimulation System Study) trial is a prospective, multicenter, single-arm, open-label clinical study of 151 adult women (mean age 58.8 years) with UUI (urgency urinary incontinence; overactive bladder-wet syndrome [OAB-wet]). The trial evaluated the efficacy and safety of Revi in treating UUI symptoms in patients with OAB-wet. Primary efficacy and safety endpoints were assessed at six and 12 months, with 97 participants completing the 24-month assessment. Revi is the first iTNM device for the treatment of UUI labeled for use without prior failure of more conservative therapies, including medication. With concerns 3 about the potential link between anticholinergic agents and dementia risk, there is an increased need for flexible, non-pharmacologic treatment options. For more information on BlueWind Medical and the Revi System, please visit About BlueWind Medical Ltd. BlueWind Medical is transforming the field of neuromodulation therapy through the development of innovative, patient-centric medical technology for the treatment of disease. BlueWind is committed to enhancing the quality of life and overall well-being of patients with an initial focus on those living with urge urinary incontinence (UUI). BlueWind's Revi® System is the first and only implantable tibial neuromodulation device activated by a battery-operated external wearable to receive FDA clearance for patients with UUI. Revi is the only neuromodulation therapy on the market that allows physicians to use their discretion to determine whether the patient should fail or not tolerate more conservative treatments before using the Revi System rather than mandating 'step-therapy.' For additional information about BlueWind Medical, please visit
Yahoo
07-02-2025
- Health
- Yahoo
BlueWind Medical Announces Peer-Reviewed Data Showing Excellent Durability of Results for Revi® System at Two Years
Findings published in the Journal of Urology demonstrate high patient satisfaction and durable outcomes with the Revi® System PARK CITY, Utah, February 07, 2025--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and developer of the Revi® System, a patient-centric solution for urgency urinary incontinence (UUI), announced today the publication of two-year results from the pivotal OASIS study in the March 2025 issue of the Journal of Urology. The OASIS study is a prospective, multicenter, single-arm, open-label clinical study of 151 adult women (mean age 58.8 years) with UUI (urgency urinary incontinence; overactive bladder-wet syndrome [OAB-wet]). The trial evaluated the efficacy and safety of Revi in treating UUI symptoms in patients with OAB-wet. Primary efficacy and safety endpoints were assessed at six and 12 months, with 97 participants consenting to and completing the 24-month assessment. Key findings at two years demonstrate Revi's durable efficacy, highly favorable safety profile, and high patient satisfaction, supporting its use for treating UUI. Notably, a sustained therapy response was observed utilizing a more flexible provider and patient-driven schedule in year two (≥ two 30-minute sessions/week) compared to the first year (30-minute daily sessions). Patients averaged at least one treatment session on eight of 10 days, tailored to individual symptom needs. The OASIS study's two-year analysis demonstrated that Revi provided sustained therapy response with: Durable reduction in UUI episodes, with 79% of participants experiencing a ≥50% reduction in UUI episodes and 56% achieving a ≥75% reduction in UUI High satisfaction rates, with 97% of the participants satisfied and 97% reporting feeling "better" to "very much better" Freedom from leaks with 28% of patients dry on a three-day voiding diary Substantial reduction in large volume urgency-related leaks, one of the most debilitating aspects of UUI, from 0.9/day to 0.1/day An excellent safety profile, with no (0%) device- or procedure-related serious adverse events, no device migrations, and no device revision procedures "What sets Revi apart is its patient centricity. The system allows patients to tailor treatment intervals to their symptoms and providers to individualize treatment plans to each patient," said John Heesakkers, M.D., Chairman of the Department of Urology of the Maastricht University Medical Center in the Netherlands. "It is encouraging to see that the OASIS study long-term data continues to validate the Revi System as a durable and effective treatment for UUI." With recent concerns about the potential link between anticholinergic agents and dementia risk, there is an increased need for flexible, non-pharmacologic treatment options. Revi is the first iTNM device for the treatment of UUI labeled for use without prior failure of more conservative therapies. Revi, with its unique label, offers an effective treatment option, supported by the newly updated 2024 Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder from the American Urological Association and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, which advocates for early consideration of minimally invasive therapy and emphasizes shared decision-making in OAB and UUI management. "The two-year study results affirm the Revi System's significant impact in improving OAB and UUI symptoms and underscore its innovation and effectiveness as a minimally invasive neuromodulation option," said Roger Dmochowski, M.D., Chief Medical Advisor, BlueWind Medical. "Our commitment remains steadfast to enhancing treatment options and elevating the quality of life for people grappling with UUI." For more information on BlueWind Medical and the Revi System, please visit About BlueWind Medical Ltd. BlueWind Medical is transforming the field of neuromodulation therapy through the development of innovative, patient-centric medical technology for the treatment of disease. BlueWind is committed to enhancing the quality of life and overall well-being of patients with an initial focus on those living with urge urinary incontinence (UUI). BlueWind's Revi® System is the first and only implantable tibial neuromodulation device activated by a battery-operated external wearable to receive FDA clearance for patients with UUI. Revi is the only neuromodulation therapy on the market that allows physicians to use their discretion to determine whether the patient should fail or not tolerate more conservative treatments before using the Revi System rather than mandating "step-therapy." For additional information about BlueWind Medical, please visit View source version on Contacts Media Contact For BlueWind MedicalAlexander Romero-Wilsonalexander@
